Using Lifetime Risk Estimates in Personal Genomic Profiles: Estimation of Uncertainty  by Yang, Quanhe et al.
ARTICLE
Using Lifetime Risk Estimates
in Personal Genomic Profiles:
Estimation of Uncertainty
Quanhe Yang,1,* W. Dana Flanders,3 Ramal Moonesinghe,2 John P.A. Ioannidis,4,5 Idris Guessous,3
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Personal genome tests are now offered direct-to-consumer (DTC) via genetic variants identiﬁed by genome-wide association studies
(GWAS) for common diseases. Tests report risk estimates (age-speciﬁc and lifetime) for various diseases based on genotypes at multiple
loci. However, uncertainty surrounding such risk estimates has not been systematically investigated. With breast cancer as an example,
we examined the combined effect of uncertainties in population incidence rates, genotype frequency, effect sizes, and models of joint
effects among genetic variants on lifetime risk estimates.We performed simulations to estimate lifetime breast cancer risk for carriers and
noncarriers of genetic variants. We derived population-based cancer incidence rates from Surveillance, Epidemiology, and End Results
(SEER) Program and comparative international data. We used data for non-Hispanic white women from 2003 to 2005. We derived geno-
type frequencies and effect sizes from published GWAS and meta-analyses. For a single genetic variant in FGFR2 gene (rs2981582),
combination of uncertainty in these parameters produced risk estimates where upper and lower 95% simulation intervals differed by
more than 3-fold. Difference in population incidence rates was the largest contributor to variation in risk estimates. For a panel of
ﬁve genetic variants, estimated lifetime risk of developing breast cancer before age 80 for a woman that carried all risk variants ranged
from 6.1% to 21%, depending on assumptions of additive or multiplicative joint effects and breast cancer incidence rates. Epidemiologic
parameters involved in computation of disease risk have substantial uncertainty, and cumulative uncertainty should be properly recog-
nized. Reliance on point estimates alone could be seriously misleading.Introduction
Recent genome-wide association studies (GWAS) have
identiﬁed several hundreds of genetic variants associated
with many common diseases and traits, and the list is
likely to grow rapidly.1 These newly detected genetic vari-
ants are relatively common in the general population,
but the associated relative risks for diseases are usually
small or moderate.2,3 At the present time, these identiﬁed
genetic variants account for a small portion of the indi-
vidual variation in disease risks, and many more variants
remain to be discovered to account for the residual genetic
‘‘dark matter.’’1 Nevertheless, the identiﬁcation of
common disease susceptibility variants through GWAS
has opened the possibility to develop more personalized
approaches, e.g., through personal genomic proﬁles, for
risk assessment and common disease prevention.4–12 By
the end of 2008, more than 30 companies were offering
direct-to-consumer (DTC) genetic tests for health-related
and nonhealth applications in many countries and a few
offer whole-genome scans.13,14 These companies provide
consumers with the estimated individual risks for a range
of diseases/conditions based on a panel of genetic variants
that have been discovered from GWAS and candidate gene
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everyday practice, many issues need to be studied and
many knowledge gaps need to be ﬁlled.3,15–20 Estimation
of the lifetime risk of developing a common disease is a
part of the clinical validity of genetic testing that exam-
ines the accuracy with which a genetic test predicts a clin-
ical outcome.21 Lifetime risk assessments of anticipated
disease occurrence are population dependent and sensi-
tive to the uncertainties and variations in the baseline
incidence of disease, genotype frequencies, and risk
associated with the genetic variants in different popula-
tions, as well as the way that gene-gene and gene-environ-
ment risk factors act interactively.2,13,16,18 Without careful
consideration of these issues, lifetime risk estimates
could be seriously misleading. However, the companies
offering DTC genetic testing provided no information
on the extent of uncertainties accompanying these risk
estimates.
We quantify the effects of several epidemiologic param-
eters on the amount of uncertainties in risk estimates for
breast cancer (MIM 114480) by using a single or a panel
of genetic variants. We also discuss the public health impli-
cations of this uncertainty. The issues we discuss are readily
applicable to other common diseases of public health
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Material and Methods
Estimations of Age-Speciﬁc Incidence Rate among
Carriers of Genetic Variants
Accurate estimates of age-speciﬁc incidence rates and lifetime risk
associated with disease-susceptibility genetic variants are ideally
derived from properly designed and conducted prospective cohort
studies that could take decades and involve substantial costs.22,23
If such information is not available, one may use population-
based disease registries and case-control studies to estimate the
age-speciﬁc incidence rates and lifetime risk associated with
disease-susceptibility genetic variants.24–29 First, one needs to esti-
mate the age-speciﬁc incidence rates among carriers of genetic
variants. In brief, for a single genetic variant (SNP), the age-speciﬁc
incidence rates among carriers can be estimated by Bayes’
theorem:
PkðD jGÞ ¼ PkðG jDÞPkðDÞ½PkðG jDÞPkðDÞ þ PkðG jDÞð1 PkðDÞÞ
(1)
where Pk(DjG) is the annual risk of disease among people with
a genetic variant in the kth age interval, k ¼ 1,2,3,.n; Pk(GjD)
and PkðGjDÞ are the prevalence of genetic variant among case
and control subjects, respectively; and Pk(D) is population inci-
dence rate in the kth age interval.
If estimates of risk ratio for disease among carriers of the genetic
variant and the prevalence of risk genotype in the population are
available, the age-speciﬁc incidence rate among carriers can also be
obtained by:
PkðD jGÞ ¼ jkPkðDÞ½PkðGÞðjk  1Þ þ 1
(2)
where ck is risk ratio for disease among carriers of genetic variant in
the kth age interval andPk(G) is theprevalenceof thegenetic variant
in a population. One can also estimate the age-speciﬁc incidence
rate among carriers of multiple genetic variants (Appendix). The
age-speciﬁc incidence rate among noncarriers of genetic variant
might be obtained by: PkðDjGÞ ¼ PkðDÞ=½jkPkðGÞ þ ð1 PkðGÞÞ.
Lifetime Risk Models
Lifetime risk of developing breast cancer is derived with life-table
methods adjusted for the competing risk of deaths. Estimates of
the lifetime risk are computed on the basis of population-based
age-speciﬁc breast cancer incidence rates and all-causes (excluding
breast cancer) mortality rates. Detailed descriptions of the meth-
odology have been published elsewhere.28–30 In the estimates of
lifetime risk among the carriers of the genetic variants, we have
replaced the population-based age-speciﬁc incidence rates with
our estimated age-speciﬁc incidence rates as described in the
previous section.
With the above proposed approach, lifetime risk for people with
a speciﬁc genetic proﬁle can be estimated if values of the popula-
tion disease incidence rates, mortality rates, genotype risk ratio,
genotype frequency, and the joint effects of multiple genetic vari-
ants are speciﬁed. Uncertainty and variation in these parameters
(sensitive parameters) would result in uncertainty in the lifetime
risk estimates. Among these sensitive parameters, the genotype
risk ratio and genotype frequency were derived from the GWAS
that involved the uncertainty in their estimates. We deﬁned their
effects on lifetime risk estimates as the uncertainty effects.
We deﬁned the changes in population incidence rates and
the assumed mode of joint effects of multiple genetic variants
on lifetime risk estimates as the variation effects because the inci-The Americandence rates might vary by populations and the joint effect of
multiple genetic variants vary by the assumption of mode of inter-
action.
Uncertainty and Variation of the Sensitive Epidemiologic Parameters
Incidence of Breast Cancer and Mortality Rates. For simplicity of illus-
tration, we focused our analysis on white populations. For the
breast cancer incidence rates, we used the age-speciﬁc incidence
rates and mortality rates of non-Hispanic white women in 2003–
2005 U.S. derived from DevCan software (version 6.3.1). DevCan
takes cross-sectional counts of cancer incident cases from the
Surveillance, Epidemiology, and End Results (SEER) Program con-
ducted by the National Cancer Institute andmortality counts from
data collected by the National Center for Health Statistics/CDC.
We focused our analysis on the changes in breast cancer incidence
rates and assumed that themortality rates other than breast cancer
were the same among the carriers of genetic variants as that in the
general population.
The incidence of breast cancer varies greatly in countries of
majority white populations, from 43 in Eastern Europe to 125
per 100,000 women in the U.S.31,32 To examine the effect of
changes in breast cancer incidence rates on lifetime risk estimates,
we took the age-speciﬁc incidence rates of non-Hispanic white
women in the U.S. as the high end and downward adjusted the
incidence rates by 3-fold (to approximately match the incidence
rate in Eastern Europe) as the low end; this deﬁned the variation
range of breast cancer incidence rates.
Relative Risks.ManyGWAS have reported only allelic odds ratios.
For simplicity of illustration, we calculated and used the dominant
genotype odds ratio as derived from the reported risk allele
frequency and allelic odds ratio. We assumed Hardy-Weinberg
equilibrium (HWE) for both controls and cases to convert allelic
odds ratios to genotype odds ratios. Even though HWE might
not hold for cases in reality, we made this assumption to illustrate
ourmethod.33 The odds ratio from case-control association studies
is used as a proxy of the population-level risk ratio. For more
common conditions, one could apply the simple method to
correct the odds ratio to better approximate risk ratio in popula-
tion.34 We selected ﬁve SNPs that were robustly associated with
breast cancer risk and replicated by GWAS and subsequent replica-
tion studies in multiple populations: SNP (rs2981582) in FGFR2
gene (MIM 176943) on chromosomes 10q26, SNP (rs3803662) in
TNRC9 gene (TOX3 [MIM 611416]) on 16q12, SNP (rs13387042)
on 2q35, SNP (rs889312) in MAP3K1 gene (MIM 600982) on
5q11, and SNP (rs3817198) in LSP1 gene (MIM 153432) on
11p15.35–37
We used random effects models to calculate the summary odds
ratio and 95% prediction interval (PI) based on the studies with
available data for each of the ﬁve SNPs.38 The meta-analyses
included 19 studies of white populations derived from Easton
et al. and Stacey et al. studies’ supplementary information.35,37
Data in four studies on rs3803662 in TNRC9 were missing in
Easton et al.,35 and we also included ﬁve studies on rs3803662
in TNRC9 from the Stacey et al. study (total 20 studies).37 For
SNP rs13387024 on 2q35, we included ﬁve studies from the Stacey
et al. study.37 These case-control studies included the population-
based, hospital-based, and convenient samples. To properly
account for the heterogeneity in relative risk estimates across the
populations, we calculated the 95% PI that provided the most
appropriate measure of uncertainty of the summary odds ratio
estimates, especially when estimates are to be extrapolated to
people beyond those tested in the original research study; this is
exactly the case when a test is going to be used in the widerJournal of Human Genetics 85, 786–800, December 11, 2009 787
population.38 PI is calculated by taking into account the variance
among the studies, t2, and is given by:
m5tak2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
t2 þ SEðmÞ2
q
where tak2 is the 100(1  a/2) percentile of the t distribution with
k-2 degrees of freedom.38 However, the test for heterogeneity of
the odds ratio indicated that the point estimate of t2 ¼ 0 for all
ﬁve SNPs included in our study, so the 95% PI approximates
95% CI (any difference is due only to the difference of the t value
with k-2 degrees of freedom versus the z distribution value for the
(1  a/2) percentile).39 We used the lower and upper 95% PI as the
uncertainty range of the effect size of the odds ratio. The 95% PI
shows the range within which the true odds ratio is likely to lie
in 95 of 100 populations similar to those where data are already
available. Even this range is already based on a conservative
assumption, because it assumes that the populations genotyped
in the case-control studies that have identiﬁed these associations
were representative of all the white populations. If we assume
t2 ¼ 0.05 (a low) and t2 ¼ 0.25 (a modest heterogeneity) that typi-
cally cannot be excluded by the 95% CIs of the t2 for SNPs arising
from GWAS investigations, then the PI would be considerably
wider (not shown in detail; available upon request).
Genotype Frequencies. The GWAS publications did not contain
detailed information to estimate the dominant genotype frequen-
cies for each speciﬁc study.35,37 We derived the dominant
genotype frequencies and their 95% conﬁdence intervals (CI) of
SNP (rs2981582) in the FGFR2 gene, SNP (rs3803662) in the
TNRC9 gene, SNP (rs889312) in the MAP3K1 gene, and SNP
(rs3817198) in the LSP1 gene from the Carcia-Closas et al. study.40
The study provided the pooled genotype frequencies of four
genetic variants from 17 case-control studies of white populations
with more than 23,000 control subjects. For SNP (rs13387042) on
2q35, we derived the genotype frequency from the Antoniou et al.
study of common genetic variants and breast cancer risk.41 The
study provided the pooled genotype frequency from 33 study
centers of white populations of BRCA1 and BRCA2 mutation
carriers. We assumed the independence between BRCA1/BRCA2
mutation and the SNP on 2q35 and used the unaffected (breast
cancer) carriers (n ¼ 4268) to derive the dominant genotype
frequency and 95% CI. Neither study provided detailed informa-
tion for each speciﬁc study to calculate 95% PI. We used the lower
and upper 95% CI as the uncertainty range of genotype
frequency.
Joint Effects of Multiple Risk Variants. For the panel of ﬁve genetic
variants, we considered three scenarios: (1) women who carry no
risk genotype; (2) women who carry three risk genotypes (SNP
[rs2981582] in FGFR2 gene, SNP [rs3803662] in TNRC9 gene,
and SNP [rs13387042] on 2q35); and (3) women who carry all
ﬁve genetic variants. We calculated the joint effect of three or
ﬁve SNPs on additive scale as: Radd ¼ R1 þ R2 þ R3  2, or Radd ¼
R1 þ R2 þ R3 þ R4 þ R5  4, where R1, R2,.,R5, are risk ratio of
disease for subjects with risk genotype compared with subjects
without risk genotype,42,43 and we repeated the same calculation
with the lower and upper 95% PI of risk ratio for each genetic
variant as the lower and higher risks range of joint effect of three
or ﬁve SNPs on additive scale.We deﬁned this range of risk ratios as
the variation range of joint effect on the additive scale. For the
joint effect on the multiplicative scale, we estimated Rmult ¼
R1*R2*R3 or Rmult ¼ R1*R2*R3*R4*R5,42,43 estimated the lower and
upper risks of joint effect as for the additive model, and deﬁned
them as the variation range on multiplicative scale. The ﬁve788 The American Journal of Human Genetics 85, 786–800, DecembSNPs have no linkage disequilibrium among them, so indepen-
dence of effects is reasonable.
Uncertainty Analysis
For uncertainty analysis, we started with one SNP in the FGFR2
gene (rs2981582) that is the most signiﬁcantly associated SNP
with breast cancer risk. It also has the largest effect size among
the ﬁve SNPs we considered.35 First, we estimated age-speciﬁc inci-
dence rates and lifetime risk of developing breast cancer among
FGFR2 carriers and noncarriers. Then, we examined separately
the effect of changes in each sensitive parameter one at a time,
e.g., changes in breast cancer incidence rates, genotype risk ratio,
and frequency followed by the combination of changes in these
parameters on lifetime risk estimate. For examining the effect of
change in each sensitive parameter on lifetime risk, we held the
other parameters at their point estimates. For example, to
examine the effect of changes in the breast cancer incidence
rate, we used formula (2) by keeping the genotype risk ratio and
frequency at their point estimates and unchanged, and ﬁrst,
used the age-speciﬁc breast cancer incidence rates of U.S. non-
Hispanic women in 2003–2005 to estimate the age-speciﬁc inci-
dence rates and the lifetime risk for the carriers of genetic variant
and noncarriers. Then we replaced the U.S. non-Hispanic
women’s rates with the 3-fold downward-adjusted age-speciﬁc
breast cancer incidence rates, and the difference between these
two estimates was documented. We repeated the similar analysis
for the genotype risk ratio and frequency. However, because we
used the pooled estimate across multiple studies for the genotype
frequencies, the 95% CI is too narrow to demonstrate any
substantial impact of the genotype frequency on risk estimate.
Ideally, one would use data from each study and combine these
frequencies with random effects to calculate the 95% PI covering
the full range of uncertainty. To further examine the impact of
uncertainty of genotype frequency and risk ratio (we also included
risk ratio as a comparison of the relative impact of changes in
genotype frequency and risk ratio on lifetime risk), we assumed
that the genotype frequency and risk ratio were 10% and 20%
lower or higher than the point estimate and documented the
changes in lifetime risk estimates among the carriers of FGFR2
genetic variant.
For themultiple genetic variants, we used formulas (1) and (2) in
the Appendix to estimate the effects of additive versus multiplica-
tive joint effects of different combination of genetic variants on
the age-speciﬁc incidence rates and lifetime risk of developing
breast cancer.
To account for the uncertainties and variations in the sensitive
epidemiologic parameters, we used the Monte Carlo simulation
methods.44,45 We assumed that the observed age-speciﬁc breast
cancer incidences and mortality rates follow the Poisson distribu-
tion (when the observed breast cancer incidences or the deaths by
age group were large [n > 1000], and we used the normal distribu-
tion to approximate the Poisson distribution). For genotype risk
ratio and frequency, we assumed a normal distribution with the
mean being the point estimate and standard deviation given by
the difference of the lower (L) and upper (U) 95% boundaries
divided by 3.92, because of the relatively large sample size for
many GWA studies.35–37 For joint effects of multiple SNPs, we
calculated the risk ratios of joint effect on additive or multiplica-
tive scales as deﬁned above.We took the lower 95% PI of risk ratios
or the upper 95% PI of different combination of multiple SNPs as
the lower 95% CI or upper 95% CI of the joint risk ratio on addi-
tive or multiplicative scale, respectively. We assumed a normal
distribution with the mean being the point estimate and standarder 11, 2009
Table 1. Dominant Genotype Frequencies and Odds Ratios for
Association between Five Selected SNPs and Breast Cancer Risk in
White Populations
Locus SNP
Dominant
Genotype
Frequencya % 95% CI
Dominant
Genotype
ORb 95% PIc
FGFR2 rs2981582 61.7 61.1–62.3 1.35 1.29–1.41
TNRC9 rs3803662 45.8 45.2–46.5 1.28 1.23–1.33
2q35 rs13387042 75.9 74.6–77.2 1.28 1.14–1.43
MAP3K1 rs889312 47.6 46.9–48.2 1.15 1.10–1.20
LSP1 rs3817198 51.7 51.0–52.3 1.10 1.06–1.15
Meta-analyses included 19 studies of white populations derived from the
Easton et al. and Stacey et al. studies.37,39 Data in four studies on rs3803662
in TNRC9 was missing in the Easton et al. study,37 so we included additional
five studies from Stacy et al. study.39 Meta-analysis of SNP rs13387024 on
2q35 included five studies from the Stacey et al. study.39 Abbreviations: CI,
confidence interval; PI, prediction interval.
a Dominant genotype frequencies of the five selected SNPs were derived from
the Carcia-Closas et al. and Antoniou et al. studies.42,43
b Dominant genotype odds ratio (OR) was calculated with the meta-analysis of
the fixed effect models.
c Prediction interval was calculated via the Higgins et al. approximation
method.40deviation given by the difference of the lower (L) and upper (U)
95% boundaries divided by 3.92.
The Crystal Ball software (version 2000.2, Decisioneering, Inc.,
Denver, CO) was used for the Monte Carlo uncertainty analysis
with 10,000 draws from the above deﬁned distributions for the
model parameters. We reported the lower 2.5 and upper 97.5
percentiles of the total simulation distribution as 95% ‘‘simulation
interval’’ (SI).46Results
Table 1 presents the dominant genotype frequencies (95%
CI) and risk ratios (OR) and 95% PIs for the association
between ﬁve selected SNPs and breast cancer risk estimated
from multiple studies of white populations.35,37,40,41 The
dominant genotype risk ratio ranged from 1.10 (95% PI
1.06–1.15) for rs3817198 in LSP1 to 1.35 (95% PI 1.29–
1.41) for rs2981582 in FGFR2. The frequency of carriers
ranged from 45.8% (95% CI 45.2–46.5) for rs3803662 in
TNRC9 to 75.9% (95% CI 74.6–77.2) for rs13387042 on
2q35.
Lifetime Risk Associated with a Single Genetic Variant
Table 2 lists the data and the estimated age-speciﬁc inci-
dence rates and lifetime risk (and 95% simulation interval
[SI]) of developing breast cancer from birth among carriers
of FGFR2 variant, noncarriers, and in the overall popula-
tion. Assuming constant genotype frequency and risk ratio
across age group, the estimated lifetime risk of developing
breast cancer from birth among carriers of FGFR2 variant
and noncarriers by age 80 years was about 2.3% higher
and 1.8% lower than the average risk in population
(15.7% and 11.6% versus 13.4%), respectively.
Holding other parameters at their point estimates, the
lifetime risk of developing breast cancer from birth to ageThe American80 years reduced from 15.7% to 5.3% among carriers of
FGFR2 variant, and from 11.6% to 3.9% among noncar-
riers, respectively, if the population incidence rates were
3-fold lower (Figure 1A). Changes in genotype risk ratio
(lower or upper 95% PI) in the population have limited
impact on lifetime risk estimates (Figure 1B) and changes
in genotype frequency (lower or upper 95% CI) have negli-
gible impact because of the narrow 95% CI (Figure 1C).
However, changes in combinations of these parameters
resulted in 5.2% to 15.9% lifetime risk of developing breast
cancer from birth to before age 80 years among carriers of
FGFR2 variant, and 3.8% to 12.1% lifetime risk among
noncarriers (Figure 1D). Difference in population breast
cancer incidence rates was the largest contributor of varia-
tion in lifetime risk estimates.
A 10% assumed variation in the genotype frequency of
FGFR2 genetic variant (55.5% to 67.9%) produced a 0.5%
difference in lifetime risk from birth to before age 80 years,
and a 20% variation (49.4% to 74.0%) produced a 1.0%
difference (Figure 2A). A 10% (1.22 to 1.42) or 20% (1.08
to 1.62) variation in genotype risk ratio produced 1.0%
or 2.0% difference in lifetime risk from birth to before
age 80 years, respectively (Figure 2B).Lifetime Risk among Women with Multiple Genetic
Variants
Approximately 22% or 5% of non-Hispanic white women
were carriers of three or all ﬁve selected genetic variants,
respectively. The estimated additive joint effect of three
genetic variants was 1.9 (95% CI 1.7–2.2) versus 2.2 (95%
CI 1.8–2.7) for the multiplicative model. The correspond-
ing comparison was 2.2 (95% CI 1.8–2.5) versus 2.8 (95%
CI 2.1–3.7) for ﬁve genetic variants. Within the same inci-
dence rates, both age-speciﬁc incidence rates and lifetime
risk from birth were substantially higher assuming multi-
plicative joint effect of multiple genetic variants than
that of additive joint effects (Table 3). The estimated life-
time risk of developing breast cancer from birth to before
age 80 years among women who carry three genetic vari-
ants ranged from 5.8% (95% SI 5.5–6.1) assuming additive
joint effect and 3-fold lower breast cancer incidence rates
to 18.7% (95% SI 17.3–20.1) assuming multiplicative joint
effects of multiple genetic variants and U.S. non-Hispanic
women breast cancer incidence rates in 2003–2005. The
corresponding lifetime risk estimates ranged from 6.1%
(95% SI 5.7–6.5) to 21.0% (95% SI 18.8–23.3) among
women who carry all ﬁve genetic variants (Table 3).Discussion
There are many issues to be considered in the evaluation of
personal genomic proﬁles including analytical and clinical
validity, clinical utility, and ethical, legal, social, and policy
implications.3,10,12,13,15–20,47 Risk assessment is part of
clinical validity studies in genetic testing. Our results
suggest that extreme caution is needed when using geneticJournal of Human Genetics 85, 786–800, December 11, 2009 789
Table 2. Lifetime Risk of Developing Breast Cancer from Birth among Carriers of FGFR2 Variants, Noncarriers, and in General Population
FGFR2 Variant Carriers Noncarriers
U.S. Non-Hispanic
White Women in 2003–2005
Age, yrs
Breast Cancer
Incidence Rates,
per 100,000
Genotype Frequency
in Population (%)
(95% CI)
Dominant
Risk Ratio
(95% PI)a
Age-Specific
Incidence Rates,
(95% SI)b (per 100,000)
Lifetime Risk %
(95% SI)b
Age-Specific
Incidence Rates
(95% SI)b (per 100,000)
Lifetime
Risk %
(95% SI)b
Lifetime Risk,
% (95% CI)c
0–19 0.05 61.7 (61.1–62.3) 1.35 (1.29–1.41) 0.1 (0.0–0.1) 0.0 (0.0–0.0) 0.0 (0.0–0.1) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
20–24 1.6 61.7 (61.1–62.3) 1.35 (1.29–1.41) 1.8 (1.3–2.2) 0.0 (0.0–0.0) 1.3 (1.0–1.7) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
25–29 8.5 61.7 (61.1–62.3) 1.35 (1.29–1.41) 9.4 (8.3–10.5) 0.1 (0.0–0.1) 6.9 (6.1–7.8) 0.0 (0.0–0.1) 0.1 (0.1–0.1)
30–34 30.1 61.7 (61.1–62.3) 1.35 (1.29–1.41) 33.4 (31.5–35.4) 0.2 (0.2–0.2) 24.7 (23.2–26.4) 0.2 (0.2–0.2) 0.2 (0.2–0.2)
35–39 71.1 61.7 (61.1–62.3) 1.35 (1.29–1.41) 79.0 (75.9–82.0) 0.6 (0.6–0.6) 58.5 (55.8–61.3) 0.5 (0.4–0.5) 0.6 (0.6–0.6)
40–44 157.2 61.7 (61.1–62.3) 1.35 (1.29–1.41) 174.6 (169.8–179.3) 1.5 (1.4–1.5) 129.3 (124.5–134.4) 1.1 (1.0–1.1) 1.4 (1.3–1.4)
45–49 246.4 61.7 (61.1–62.3) 1.35 (1.29–1.41) 273.6 (267.1–280.1) 2.8 (2.7–2.9) 202.7 (195.5–210.0) 2.1 (2.0–2.1) 2.5 (2.5–2.6)
50–54 298.5 61.7 (61.1–62.3) 1.35 (1.29–1.41) 331.5 (323.9–338.9) 4.4 (4.3–4.5) 245.5 (237.1–254.5) 3.3 (3.2–3.3) 4.0 (3.9–4.0)
55–59 363.7 61.7 (61.1–62.3) 1.35 (1.29–1.41) 403.8 (394.7–412.8) 6.3 (6.2–6.4) 299.0 (288.6–310.0) 4.7 (4.6–4.8) 5.6 (5.6–5.7)
60–64 439.1 61.7 (61.1–62.3) 1.35 (1.29–1.41) 487.5 (476.3–498.7) 8.6 (8.5–8.7) 361.1 (348.3–374.1) 6.4 (6.3–6.5) 7.6 (7.5–7.7)
65–69 497.3 61.7 (61.1–62.3) 1.35 (1.29–1.41) 552.1 (539.2–565.2) 11.1 (11.0–11.2) 409.0 (394.7–424.1) 8.2 (8.1–8.3) 9.7 (9.6–9.8)
70–74 507.6 61.7 (61.1–62.3) 1.35 (1.29–1.41) 563.6 (550.0–577.1) 13.4 (13.3–13.6) 417.5 (402.6–433.5) 10.0 (9.8–10.1) 11.7 (11.6–11.7)
75–79 523.8 61.7 (61.1–62.3) 1.35 (1.29–1.41) 581.5 (567.7–595.3) 15.7 (15.5–15.8) 430.8 (415.3–446.8) 11.6 (11.5–11.8) 13.4 (13.3–13.5)
80þ 429.1 61.7 (61.1–62.3) 1.35 (1.29–1.41) 476.4 (466.2–487.0) 16.8 (16.7–16.9) 352.9 (340.9–365.6) 12.5 (12.3–12.6) 15.8 (15.7–15.9)
Estimates of lifetime risk of developing breast cancer from birth among carriers and noncarriers of FGFR2 genetic variant were based on the age-specific breast cancer incidence rates of U.S. non-Hispanic white women in 2003–
2005. Abbreviations: CI, confidence interval; PI, prediction interval; SI, simulation interval.
a Prediction interval was calculated via the Higgins et al. approximation method.40
b Simulation interval was based on 10,000 Monte Carlo simulations. We assumed that the breast cancer incidence cases and number of deaths followed the Poisson distribution (when the number of cases were large
[n> 1000], normal distribution was used to approximate Poisson distribution), genotype frequency, and dominant risk ratio followed normal distribution with mean as point estimate and standard deviation as the difference
between upper and lower 95% confidence interval (CI) or 95% prediction interval (PI) divided by 3.92.
c Lifetime risk of developing breast cancer from birth among U.S. non-Hispanic white women derived from DevCan software (version 6.3.1).
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Figure 1. Effect of Epidemiologic Parameters
on Lifetime Risk of Developing Breast Cancer
from Birth among Carriers and Noncarriers of
FGFR2 Variant
Figures show the effect of breast cancer incidence
rates, risk ratio, genotype frequency, and combi-
nations of these parameters on lifetime risk of
developing breast cancer from birth among
carriers and noncarriers of FGFR2 (rs2981582)
genetic variant.
(A) Effect of 3-fold lower breast cancer incidence
rates; blue solid line with squares indicates life-
time risk of developing breast cancer among
non-Hispanic white women; red solid line with
squares indicates lifetime risk of developing
breast cancer among non-Hispanic white women
who carried FGFR2 genetic variant; red dashed
line indicates lifetime risk of developing breast
cancer among carriers of FGFR2 genetic variant
assuming a 3-fold lower breast cancer incidence
rates; green solid line with squares indicates life-
time risk of developing breast cancer among
noncarriers of non-Hispanic white women; green
dashed line indicates lifetime risk of developing
breast cancer among noncarriers assuming a
3-fold lower breast cancer incidence rates.
(B) Effect of lower and upper 95% prediction
interval (PI) of risk ratio; blue solid line with
squares indicates lifetime risk of developing
breast cancer among non-Hispanic white
women; red solid line with squares indicates
effect of using upper 95% PI risk ratio on lifetime
risk among non-Hispanic white women who
carried FGFR2 genetic variant; red dashed line
indicates effect of using lower 95% PI risk ratio
on lifetime risk among non-Hispanic white
women who carried FGFR2 genetic variant; green
solid line with square indicates effect of using
upper 95% PI risk ratio on lifetime risk among
noncarriers of non-Hispanic white women; green dashed line indicates effect of using lower 95% PI risk ratio on lifetime risk among
noncarriers of non-Hispanic white women.
(C) Effect of lower and upper 95% conﬁdence interval (CI) of genotype frequency; blue solid line with square indicates lifetime risk of
developing breast cancer among non-Hispanic white women; red solid line with squares indicates effect of using lower 95%CI genotype
frequency on lifetime risk among non-Hispanic white women who carried FGFR2 genetic variant; red dashed line indicates effect of
using upper 95% CI genotype frequency on lifetime risk among non-Hispanic white women who carried FGFR2 genetic variant; green
solid line with squares indicates effect of using lower 95% CI genotype frequency on lifetime risk among noncarriers of non-Hispanic
white women; green dashed line indicates effect of using upper 95% CI genotype frequency on lifetime risk among noncarriers of non-
Hispanic white women.
(D) Effect of combination of these parameters; blue solid line with square indicates lifetime risk of developing breast cancer among non-
Hispanic white women; red solid line with square indicates combination effect of lower 95% CI genotype frequency and upper 95% PI
risk ratio on lifetime risk among non-Hispanic white women who carried FGFR2 genetic variant; red dashed line indicates combination
effect of upper 95% CI genotype frequency and lower 95% PI risk ratio on lifetime risk among carriers of FGFR2 genetic variant
assuming a 3-fold lower breast cancer incidence rates; green solid line with square indicates combination effects of lower 95% CI geno-
type frequency and lower 95% PI risk ratio on lifetime risk among noncarriers of non-Hispanic white women; green dashed line indicates
combination effects of upper 95% CI genotype frequency and upper 95% PI risk ratio on lifetime risk among noncarriers assuming a
3-fold lower breast cancer incidence rates.variants to estimate disease risks for common complex
diseases, because the cumulative uncertainty and variation
of several epidemiologic parameters that inﬂuence the
absolute disease risk can have a major impact on risk esti-
mation.
A potentially detrimental scenario would provide
consumers with risk estimates that use inappropriate pop-
ulation incidence rates and relative risks associated with
genetic variants. Risk assessment among carriers and
noncarriers could vary substantially depending on the
uncertainties and variations in the combinations of popu-The Americanlation parameters. In particular, variations in population
incidence rates can play an important role in lifetime risk
estimates if there are marked differences across popula-
tions and ethnic groups. In our breast cancer example,
3-fold differences are documented even within white pop-
ulations.31,32 We did not consider nonwhite populations,
but the breast cancer incidence rates in Asian countries
such as China and Japan are less than one-ﬁfth or one-
fourth that of the U.S.31,32 Extrapolation to populations
of other ancestries would thus warrant further adjust-
ments. We used breast cancer as an example in ourJournal of Human Genetics 85, 786–800, December 11, 2009 791
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Figure 2. Effects of Varying Genotype Frequency and Risk Ratio
on Lifetime Risk of Developing Breast Cancer from Birth among
Carriers of FGFR2 Variant
Figures show the effect of assuming 10% or 20% lower or higher
values than the point estimates of genotype frequency and risk
ratio of FGFR2 (rs2981582) genetic variant on lifetime risk of
developing breast cancer from birth among carriers of U.S. non-
Hispanic white women in 2003–2005.
(A) Effect assuming 10% or 20% lower or higher genotype
frequency; blue solid line with squares indicates lifetime risk of
developing breast cancer among non-Hispanic white women;
red solid line with squares indicates lifetime risk among carriers
of FGFR2 genetic variant assuming 20% lower genotype
frequency; red dashed line indicates lifetime risk among carriers
of FGFR2 genetic variant assuming 10% lower genotype
frequency; green solid line with squares indicates lifetime risk
among carriers of FGFR2 genetic variant assuming 20% higher
genotype frequency; and green dashed line indicates lifetime risk
among carriers of FGFR2 genetic variant assuming 10% higher
genotype frequency.
(B) Effect assuming 10% or 20% lower or higher genotype risk
ratio; blue solid line with squares indicates lifetime risk among
non-Hispanic white women; red solid line with squares indicates
lifetime risk among carriers of FGFR2 genetic variant assuming
20% higher genotype risk ratio; red dashed line indicates lifetime
risk among carriers of FGFR2 genetic variant assuming 10% higher
genotype risk ratio; green solid line with squares indicates lifetime
risk among carriers of FGFR2 genetic variant assuming 10% lower
792 The American Journal of Human Genetics 85, 786–800, Decembanalyses and assumed 3-fold differences in population
incidence rates; it is not surprising to ﬁnd that difference
in population incidence rates was the largest contributor
to variation in lifetime risk estimates. Many common
diseases might have larger variations in population inci-
dence rates, such as diabetes (International Diabetes Feder-
ation), and others might have less variation among
different populations.48 Other studies also suggested that
the effects of genetic variants might differ by the patholog-
ical subtype of breast cancer.40 This might be the case for
other common diseases, adding more uncertainty in using
appropriate population incidence rates and genotype risk
ratios. Therefore, it is crucial that the appropriate popula-
tion incidence rates are used in lifetime risk estimates. In
addition, the rates of many common diseases might
change greatly over time. For example, the incidence of
diabetes increased 41% from 4.9 to 6.9 per 1000 popula-
tion from 1997 to 2003 in the U.S.,49 and could increase
further in the future,50 making risk estimates based on
past data obsolete. SEER is a well-established population-
based cancer registry that provides reliable estimates for
many cancers. For many other diseases, population inci-
dence rates may be unreliable or even unavailable.
Although the lifetime risk of developing breast cancer
among carriers of multiple genetic variants increased
compared with the risk in the general population, the
assumed mode of joint effect among multiple genetic vari-
ants (additive versus multiplicative) also plays an impor-
tant role in lifetime risk estimates. It remains unknown
on what scale multiple genetic variants and environment
risk factors interact to affect the risk for common diseases.
Moreover, current studies do not have adequate statistical
power to detect interactions, i.e., further signiﬁcant devia-
tions beyond these models.51 Many studies argued for
additive joint effects and others suggested that the
multiple genetic variants interact multiplicatively.52–55
Differences up to 3% can arise from consideration of multi-
plicative versus additive models alone among carriers of
ﬁve genetic variants in our study.
However, compared to the variations in the population
incidence rates and the assumed mode of joint effect of
multiple genetic variants, the impact of uncertainties in
the genotype risk ratio and frequency have little impact
on lifetime risk estimates given that the risk associated
with each SNP is moderate (RR < 1.5) and the genotype
frequencies are common (>45%) in our study. For
example, it appeared that a 10% variation around the
point estimate of the common genotype frequency (SNP
in FGFR2 with a genotype frequency 61.7%) might
produce ~0.5% difference, and a 10% variation in geno-
type risk ratio (SNP in FGFR2 with a genotype risk ratio
1.35) is associated with ~1.0% difference in lifetime risk
of developing breast cancer from birth to before agegenotype risk ratio; and green dashed line indicates lifetime risk
among carriers of FGFR2 genetic variant assuming 20% lower
genotype risk ratio.
er 11, 2009
80 years. There is no objective criteria concerning what
changes might be considered substantial in lifetime risk
estimates. From a practical point of view, <1.0% difference
in lifetime risk might not be considered substantial. For
strong-effect SNP with less common frequency in popula-
tion, differences in risk ratio and genotype frequency could
have signiﬁcant impact on lifetime risk estimates (results
not shown).56 Presently, most GWAS have studied white
populations, but the risk genotype frequencies and their
associated risk might differ more for different popula-
tions.57–61
We used ﬁve selected SNPs for breast cancer that were
conﬁrmed by GWAS as an example in our analysis. There
is preliminary evidence from some diseases such as type
1 and type 2 diabetes, hyperlipidemia, and Crohn’s disease
and theoretical reasons to believe that many common
diseases are caused by a large number of common genetic
variants that have weak effect each but high risk acting
jointly.62 It is widely accepted that one variant or even
ﬁve of them typically would have limited predictive
ability.63,64 In the near future, as more of the genetic archi-
tecture of complex diseases is discovered, it should become
more feasible to use many genetic variants that explain
a larger share of the disease variance. One may speculate
whether this would make a difference in our inferences.
To examine the effects of many common genetic variants
on lifetime risk estimates, we simulated a population
with 100 SNPs assuming the genotype risk ratio ¼ 1.1
and genotype frequency ¼ 10% for each SNP. Assuming
normal distribution of the number of SNPs, 95% of people
would have between 4 and 16 SNPs in the simulated pop-
ulation.64 By using the same incidence rates of non-
Hispanic white women in 2003–2005 U.S., we calculated
lifetime risks among the carriers of 10 or 20 SNPs for addi-
tive and multiplicative joint effect models, respectively.
The lifetime risk of developing breast cancer from birth
to before age 80 years increased from 25.5% to 34.8%
among the carriers of 10 to 20 SNPs, assuming additive
joint effects. It increased from 32.7% to 74.5% assuming
multiplicative joint effects. It is possible to use themultiple
SNPs to identify the high-risk individuals in population if
used appropriately.55,65 Nevertheless, the uncertainty and
variation in crucial parameters as those that we have eval-
uated is unlikely to diminish and therefore substantial
uncertainty around the point estimates may remain
typical. The inappropriate application of lifetime risk esti-
mate via GWAS-identiﬁed genetic variants could lead to
misleading results and provide little help or even harm to
consumers seeking risk assessments for common diseases.
In this report, we focused our analysis on the impact of
joint effects of multiple genetic variants on lifetime risk
estimates. In reality, it is important to consider the impact
of gene-environment interactions. Many environment risk
factors are common and have substantial larger effect size
compared to the genetic variants. For example, the relative
risk for breast cancer was 1.9 for women who ﬁrst gave
birth after age 30 years to those who gave their ﬁrst birthThe Americanbefore age 30 years, with an estimated 21% of non-
Hispanic white women giving birth after age 30 years in
U.S.66,67 Depending on the mode of gene-environment
interaction, the difference in lifetime risk could be substan-
tial between those who are exposed and not exposed to
environment risk factors.
We used an established and validated method to esti-
mate the lifetime risk by using information derived from
population-based disease registries and case-control
studies that takes into account the competing risk.24–29
Several companies offer genome-wide scans and provide
lifetime risk estimate for the selected common diseases/
conditions.13,18 The predicted individual lifetime risk was
obtained by multiplying the overall risk relative to popula-
tion with the ethnicity- and region-speciﬁc average life-
time risk (Personalized Medicine Coalition). None of the
companies has systematically examined the impact of
multiple sources of uncertainty and variation of the epide-
miologic parameters used in risk estimates, nor have any
taken into account the effect of competing risk in their
risk estimates. Without carefully considering the potential
impact of the multiple sources of uncertainty and varia-
tion, personal genome tests could lead to inconsistent or
misleading results in informing consumers on their disease
risks and potential measures for disease prevention. The
use of inappropriate methods would likely add additional
uncertainty as well as inaccuracy in risk estimates. For
example, mammography is an accepted preventive/
screening measure for breast cancer, even if there is debate
about its merits and indicated age of screening.68,69 It has
been argued that genetic testing might modify the indi-
cated age of screening and might suggest that some
women are at sufﬁciently low risk for screening not to be
indicated.65 However, this assumption relies on the ability
to accurately estimate the lifetime risk, and this is not
straightforward. Our analysis indicates that combined
with variations in breast cancer incidence rates, uncer-
tainties in the genotype frequencies, and the associated
risk, the estimated lifetime risk of developing breast cancer
can rangemore than 3-fold for a single genetic variant. The
range of uncertainty in lifetime risk estimates is likely to be
wider when considering gene-gene and gene-environment
interactions.
There are some limitations to our approach. First, we
assumed constant risk ratio across age groups. Neverthe-
less, there is no evidence for age modulation of the genetic
effects. Second, we assumed that themortality rates among
carriers of genetic variants were the same as that of the
general population. This assumption might be reasonable
for a single GWAS genetic variant, but may be more ques-
tionable among carriers of multiple genetic variants. Simu-
lations assuming that both total mortality and mortality
rates other than cancer were 20% lower versus 20% higher
than that of the population average among carriers of ﬁve
genetic variants yielded relatively small differences (up to
0.7%) in the estimated lifetime risk of breast cancer (not
shown in detail).Journal of Human Genetics 85, 786–800, December 11, 2009 793
Table 3. Lifetime Risk of Developing Breast Cancer from Birth among Noncarriers and Carriers of Three and Five Genetic Variants
Noncarriers Carriers of Three SNPs Carriers of Five SNPs
Using U.S. Breast
cancer Incidence
Rates of Non-
Hispanic White
Women in
2003–2005
Assuming 1/3
of U.S. Breast
Cancer Incidence
Rates of Non-
Hispanic White
Women in
2003–2005
Using U.S. Breast
Cancer
Incidence
Rates of Non-
Hispanic White
Women in
2003–2005
Assuming 1/3
of U.S. Breast
Cancer Incidence
Rates of Non-
Hispanic White
Women in
2003–2005
Using U.S.
Breast Cancer
Incidence
Rates of Non-
Hispanic White
Women in
2003–2005
Assuming 1/3
of U.S. Breast
Cancer
Incidence
Rates of Non-
Hispanic White
Women in
2003–2005
Age
(years)
Age-Specific
Incidence
Rates
(95% SI)
(per 100,000)a
Lifetime
Risk, %
(95% SI)a
Age-Specific
Incidence
Rates
(95% SI)
(per 100,000)a
Lifetime
Risk, %
(95% SI)a
Age-Specific
Incidence
Rates
(95% SI)
(per 100,000)a
Lifetime
Risk, %
(95% SI)a
Age-Specific
Incidence
Rates
(95% SI)
(per 100,000)a
Lifetime
Risk, %
(95% SI)a
Age-Specific
Incidence
Rates
(95% SI)
(per 100,000)a
Lifetime
Risk, %
(95% SI)a
Age-Specific
Incidence
Rates
(95% SI)
(per 100,000)a
Lifetime
Risk, %
(95% SI)a
Additive Modelb
0–19 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.1 (0.0–0.1) 0.0 (0.0–0.0) 0.0 (0.0–0.1) 0.0 (0.0–0.0) 0.1 (0.0–0.1) 0.0 (0.0–0.0) 0.0 (0.0–0.1) 0.0 (0.0–0.0)
20–24 1.0 (0.7–1.2) 0.0 (0.0–0.0) 0.3 (0.2–0.5) 0.0 (0.0–0.0) 2.0 (1.4–2.6) 0.0 (0.0–0.0) 0.7 (0.4–1.0) 0.0 (0.0–0.0) 2.0 (1.5–2.3) 0.0 (0.0–0.0) 0.7 (0.4–1.0) 0.0 (0.0–0.0)
25–29 5.0 (4.4–5.8) 0.0 (0.1–0.0) 1.7 (1.3–2.1) 0.0 (0.0–0.0) 10.4 (8.5–12.6) 0.1 (0.1–0.1) 3.4 (2.6–4.3) 0.0 (0.0–0.0) 10.9 (8.6–13.4) 0.1 (0.1–0.1) 3.6 (2.7–4.7) 0.0 (0.0–0.0)
30–34 17.9
(16.3–19.6)
0.1 (0.1–0.1) 5.9 (5.2–6.7) 0.0 (0.0–0.0) 36.9 (31.1–43.2) 0.2 (0.2–0.3) 12.3
(10.1–14.7)
0.1 (0.1–0.1) 39.4
(32.3–47.0)
0.2 (0.2–0.3) 12.9
(10.4–15.7)
0.1 (0.1–0.1)
35–39 42.4
(39.0–46.0)
0.3 (0.3–0.3) 14.1
(12.8–15.5)
0.1 (0.1–0.1) 87.2
(73.9–101.6)
0.7 (0.6–0.8) 29.0
(24.0–34.0)
0.2 (0.2–0.3) 91.3
(75.1–108.8)
0.7 (0.6–0.8) 30.5
(24.8–36.4)
0.2 (0.2–0.3)
40–44 93.6
(86.7–101.1)
0.8 (0.7–0.8) 31.1
(28.7–33.9)
0.3 (0.2–0.3) 193.0
(164.1–223.2)
1.6 (1.5–1.8) 64.2
(54.5–74.9)
0.5 (0.5–0.6) 201.8
(166.6–239.4)
1.7 (1.5–1.9) 67.4
(55.1–80.2)
0.6 (0.5–0.6)
45–49 146.7
(136.3–159.1)
1.5 (1.4–1.6) 48.8
(45.2–53.2)
0.5 (0.4–0.5) 302.7
(265.0–351.0)
3.1 (2.8–3.4) 100.7
(85.5–117.7)
1.1 (0.9–1.1) 316.9
(261.1–375.9)
3.3 (2.9–3.6) 105.7
(87.4–124.9)
1.1 (0.9–1.2)
50–54 177.6
(165.2–192.2)
2.4 (2.3–2.5) 59.1
(54.8–64.2)
0.8 (0.7–0.8) 366.2
(311.7–424.7)
4.9 (4.5–5.2) 121.8
(103.4–142.0)
1.6 (1.5–1.8) 383.7
(317.0–455.3)
5.1 (4.6–5.6) 127.7
(105.5–151.8)
1.7 (1.6–1.9)
55–59 216.5
(201.2–234.5)
3.4 (3.3–3.5) 72.1
(66.8–78.3)
1.1 (1.0–1.1) 445.7
(379.8–519.3)
7.0 (6.5–7.5) 148.5
(126.1–172.7)
2.3 (2.2–2.5) 466.9
(397.5–553.2)
7.3 (6.7–8.0) 155.7
(128.8–185.1)
2.5 (2.3–2.7)
60–64 261.4
(242.8–282.6)
4.6 (4.5–4.8) 87.1
(80.6–94.4)
1.5 (1.4–1.6) 539.9
(459.1–625.4)
9.5 (8.9–10.2) 179.5
(152.3–208.8)
3.2 (3.0–3.4) 564.7
(465.6–670.4)
10.0 (9.2–10.7) 187.8
(154.6–223.7)
3.3 (3.1–3.6)
65–69 296.1
(274.8–319.8)
6.0 (5.8–6.2) 98.6
(91.2–107.0)
2.0 (1.9–2.1) 610.3
(518.7–708.8)
12.2 (11.5–13.0) 202.9
(172.1–237.1)
4.1 (3.8–4.4) 640.1
(525.7–759.2)
12.8 (11.9–13.8) 212.7
(175.8–252.3)
4.3 (4.0–4.6)
70–74 302.2
(280.5–326.9)
7.2 (7.0–7.5) 100.6
(92.9–109.4)
2.4 (2.3–2.5) 621.6
(532.4–721.2)
14.9 (14.0–15.7) 207.3
(175.4–241.5)
5.0 (4.7–5.3) 652.9
(539.1–774.1)
15.6 (14.5–16.6) 217.1
(179.1–257.8)
5.2 (4.9–5.6)
75–79 311.9
(289.8–337.9)
8.4 (8.2–8.7) 103.9
(96.1–112.9)
2.8 (2.7–2.9) 642.1
(547.5–747.0)
17.3 (16.4–18.2) 214.1
(182.0–248.8)
5.8 (5.5–6.1) 674.1
(554.6–798.2)
18.1 (17.0–19.3) 224.1
(184.8–267.3)
6.1 (5.7–6.5)
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80þ 255.4
(237.3–275.8)
9.0 (8.8–9.3) 85.1
(78.7–92.2)
3.0 (2.9–3.1) 526.0
(446.7–611.5)
18.5 (17.6–19.5) 174.9
(148.7–203.6)
6.2 (5.9–6.6) 551.6
(455.3–653.5)
19.4 (18.2–20.6) 183.5
(151.9–217.7)
6.5 (6.1–6.9)
Multiplicative Modelb
0–19 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.1 (0.0–0.1) 0.0 (0.0–0.0) 0.0 (0.0–0.1) 0.0 (0.0–0.0) 0.1 (0.0–0.1) 0.0 (0.0–0.0) 0.0 (0.0–0.1) 0.0 (0.0–0.0)
20–24 0.8 (0.6–0.1) 0.0 (0.0–0.0) 0.3 (0.2–0.4) 0.0 (0.0–0.0) 2.1 (1.5–2.9) 0.0 (0.0–0.0) 0.7 (0.4–1.1) 0.0 (0.0–0.0) 2.4 (1.5–3.5) 0.0 (0.0–0.0) 0.8 (0.4–1.3) 0.0 (0.0–0.0)
25–29 4.5 (3.9–5.3) 0.0 (0.0–0.0) 1.5 (1.2–1.9) 0.0 (0.0–0.0) 11.2 (8.6–14.3) 0.1 (0.0–0.1) 3.7 (2.7–5.0) 0.0 (0.0–0.0) 12.6 (8.8–17.2) 0.1 (0.0–0.1) 4.2 (2.3–5.9) 0.0 (0.0–0.0)
30–34 16.0
(14.3–18.1)
0.1 (0.0–0.1) 5.3 (4.6–6.2) 0.0 (0.0–0.0) 40.0 (31.2–49.4) 0.3 (0.2–0.3) 13.2
(10.0–16.8)
0.1 (0.1–0.1) 44.8
(31.7–60.2)
0.3 (0.2–0.4) 14.9
(10.4–19.9)
0.1 (0.1–0.1)
35–39 38.0
(34.1–42.4)
0.3 (0.2–0.3) 12.6
(11.2–14.3)
0.1 (0.1–0.1) 94.3
(74.2–116.7)
0.7 (0.6–0.9) 31.4
(24.7–39.0)
0.2 (0.2–0.3) 106.2
(74.5–140.3)
0.8 (0.7–1.0) 35.2
(24.7–47.2)
0.3 (0.2–0.3)
40–44 83.9
(75.6–93.3)
0.7 (0.6–0.7) 27.9
(25.0–31.2)
0.2 (0.2–0.2) 209.0
(165.5–257.8)
1.8 (1.5–2.0) 69.4
(54.6–85.9)
0.6 (0.5–0.7) 235.2
(164.3–307.7)
2.0 (1.6–2.4) 78.0
(54.7–103.2)
0.7 (0.5–0.8)
45–49 131.5
(118.7–147.1)
1.4 (1.3–1.5) 43.8
(39.4–49.1)
0.5 (0.4–0.5) 326.8
(259.9–402.0)
3.4 (2.9–3.8) 108.9
(85.4–134.6)
1.1 (1.0–1.3) 367.2
(260.0–485.0)
3.8 (3.1–4.5) 122.8
(86.2–160.5)
1.3 (1.0–1.5)
50–54 159.1
(144.0–177.6)
2.1 (2.0–2.3) 52.9
(47.8–59.2)
0.7 (0.6–0.7) 396.1
(311.6–488.4)
5.3 (4.7–5.9) 132.0
(104.2–163.2)
1.8 (1.6–2.0) 446.3
(315.0–589.5)
5.9 (5.0–6.9) 148.0
(104.2–195.8)
2.0 (1.7–2.3)
55–59 194.2
(175.3–216.6)
3.1 (2.9–3.2) 64.6
(58.3-72.3)
1.0 (0.9–1.0) 483.8
(380.2–593.2)
7.6 (6.8–8.4) 160.9
(126.6–198.7)
2.5 (2.3–2.8) 542.6
(382.6–714.6)
8.5 (7.3–9.8) 180.6
(127.0–239.6)
2.9 (2.4–3.3)
60–64 234.5
(211.4–261.3)
4.2 (4.0–4.4) 78.1
(70.3–87.1)
1.4 (1.3–1.5) 582.7
(460.2–720.3)
10.3 (9.3–11.3) 194.2
(153.2–238.5)
3.5 (3.1–3.8) 656.0
(456.5–860.1)
11.5 (10.1–13.1) 218.2
(153.9–288.2)
3.9 (3.4–4.4)
65–69 265.5
(239.5–295.9)
5.4 (5.1–5.6) 88.4
(79.5–98.8)
1.8 (1.7–1.9) 662.0
(518.3–815.1)
13.3 (12.1–14.4) 220.0
(173.2–270.3)
4.5 (4.1–4.8) 744.2
(518.8–981.7)
14.9 (13.4–16.7) 247.3
(172.3–328.6)
5.0 (4.4–5.6)
70–74 271.0
(244.1–301.6)
6.5 (6.3–6.8) 90.2
(81.0–101.0)
2.2 (2.1–2.3) 674.2
(530.6–831.2)
16.1 (14.8–17.4) 224.0
(178.0–276.4)
5.4 (5.0–5.9) 755.2
(539.1–996.1)
18.0 (16.0–20.1) 252.7
(175.9–334.1)
6.1 (5.4–6.8)
75–79 279.7
(252.3–312.4)
7.6 (7.3–7.9) 93.1
(83.8–104.2)
2.5 (2.4–2.6) 697.3
(549.8–860.7)
18.7 (17.3–20.1) 231.7
(182.7–286.5)
6.3 (5.8–6.8) 781.1
(545.1–1036.6)
21.0 (18.8–23.3) 260.4
(183.7–344.5)
7.1 (6.3–7.9)
80þ 229.0
(206.8–254.9)
8.1 (7.8–8.4) 76.3
(68.6–85.1)
2.7 (2.6–2.8) 570.4
(450.2–704.6)
20.1 (18.6–21.5) 189.7
(149.3–234.0)
6.7 (6.3–7.3) 639.5
(446.6–847.5)
22.5 (20.3–24.8) 213.5
(149.8–282.3)
7.6 (6.9–8.4)
Estimates of lifetime risk of developing breast cancer from birth among noncarriers and carriers of genetic variants were based on the age-specific breast cancer incidence rates of U.S. non-Hispanic white women in 2003–2005
and by assuming 1/3 of U.S. breast cancer incidence rates. Abbreviations: CI, confidence interval; PI, prediction interval; SI, simulation interval.
a Simulation interval was based on 10,000 Monte Carlo simulations. We assumed that the breast cancer incidence cases and number of deaths followed the Poisson distribution (when the number of incidence cases or
number of deaths were large (n > 1000), normal distribution was used to approximate Poisson distribution), genotype frequency and dominant risk ratio followed the normal distribution with mean as point estimate
and standard deviation as the difference between upper and lower 95% confidence interval (CI) or 95% prediction interval (PI) divided by 3.92.
b The risk ratios of joint effect of three or five SNPs on additive or multiplicative scale were calculated as defined in Material and Methods section. We took the lower 95% prediction interval (PI) of risk ratio of each SNP,
calculated the risk ratios of joint effect on additive and multiplicative scale respectively and defined them as the minimum risk ratio in the Monte Carlo simulation. In a similar fashion, we took the upper 95% PI of risk ratio of
each SNP, calculated the risk ratios on additive and multiplicative scale and defined them as the maximum risk ratio in the simulation (defined as the triangle distribution with the mean value as the point estimate of risk ratio
on additive or multiplicative scale).
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The recent explosion of DTC personal genome tests
offered by the companies in different countries raises the
concerns among the scientiﬁc communities and oversight
groups regarding the possible health beneﬁts and the
undesired consequences for individuals.13,18,19,56,69 Our
study focused on examining the uncertainty in risk assess-
ment as part of clinical validity of genetic testing. Our
results indicated that it is important to recognize the
impact of cumulative uncertainty and variation in the
epidemiologic parameters involved in computation of
disease risk. Providing consumers with these risk estimates
without proper interpretation of the uncertainty and
variation around these estimates could be seriously
misleading.Appendix
Estimations of Age-Speciﬁc Incidence Rate among
Carriers of Multiple Genetic Variants
For simplicity, we consider N independent biallelic disease-
susceptibility loci. Let G1, G2. Gn, be genotype frequency
in population, and R1, R2,.,Rn, be the risk ratio for disease
for subjects with risk genotype compared with subjects
without risk genotype. The odds ratio from case-control
association studies is a proxy of the population-level risk
ratio. Let i1, i2,.,in, be binary numbers (0/1) depending
on the (presence/absence) of the genetic variants. We
have limited knowledge about how the multiple genetic
variants might act in consort to affect the disease risk.
There is a long debate about how to deﬁne and measure
interaction in epidemiologic studies.42,70 For simplicity,
we consider the joint effects of a panel of genetic variants
on either an additive or multiplicative scale without any
extra interaction effect.42,43 To illustrate the additive and
multiplicative effect model, let us consider two indepen-
dent biallelic disease susceptibility loci. Let G1 and G2 be
genotype frequencies in population, and let Rg11, Rg10,
and Rg01 be risk ratios of having both genetic variants,
genetic variant 1 only (G1) and genetic variant 2 only
(G2), respectively. The joint effect on an additive scale is
deﬁned as: Rg11 ¼ Rg10 þ Rg01  1. The joint effect on a
multiplicative scale is given as: Rg11¼ Rg10*Rg01. Assuming
additive effects, the age-speciﬁc incidence rate among
subjects with different combination of multiple genetic
variants is obtained by:PkðD jG1 ¼ i1,G2 ¼ i2,.,Gn ¼ inÞ ¼ PðP
i,i2,.ik
PðD jG1 ¼
¼
"
1þPn
j¼1
ij

Rj  1
1þPn
j¼1
Gj

Rj 
796 The American Journal of Human Genetics 85, 786–800, DecembAssuming multiplicative effects, the age-speciﬁc inci-
dence rate among subjects with different combination of
multiple genetic variants is obtained by:
PkðD jG1 ¼ i1,G2 ¼ i2,.,Gn ¼ inÞ
¼ R
i1
1 R
i2
2.R
in
n PðDÞ
½R1G1 þ ð1 G1Þ½R2G2 þ ð1 G2Þ.½RnGn þ ð1 GnÞ
¼
Yn
j¼1
R
ij
j PðDÞ
RjGj þ

1 Gj

(2)
Calculate Age-Speciﬁc Incidence Rate by Genotype
For a single biallelic locus with alleles A and a, there are
three possible genotypes: AA (homozygous dominant),
Aa (heterozygous), and aa (homozygous recessive). Let
G0, G1, and G2 denote the prevalence of homozygous
recessive, heterozygous, and homozygous dominant geno-
types in a population, respectively. Let c2 and c1 be risk
among subjects with genotypes AA and Aa compared
with risk among those with genotype aa, respectively.
The age-speciﬁc incidence rate among subjects with AA
or Aa genotypes can also be obtained by:
PkðD jGiÞ ¼ jkiPkðDÞ½PkðG2Þjk2 þ PkðG1Þjk1 þ PðG0Þ
(3)
where cki (I ¼ 1, 2) is risk ratio for disease among subjects
with homozygous and heterozygous genotypes in the kth
age interval, respectively; and Pk(Gi) is the prevalence of
the genotypes in a population.
Lifetime Risk Models
Lifetime and residual lifetime risk (age-conditional proba-
bility) estimates of developing breast cancer are derived
with life-table methods adjusted for the competing risk
of death. In brief, estimates of the lifetime risk of devel-
oping breast cancer are computed on the basis of popula-
tion-based age-speciﬁc breast cancer incidence rates and
all-causes (excluding breast cancer) mortality rates. A life
table is constructed for a hypothetical cancer-free cohort
of individuals who are exposed to the age-speciﬁc breast
cancer rates as they age. The number of cancer-free individ-
uals at the start of a subsequent age interval is computed by
subtracting the number who develop cancer and the
number who die of other causes from the number ofD jG1 ¼ i1,G2 ¼ i2,.,Gn ¼ inÞPðDÞ
i1,G2 ¼ i2,.,Gn ¼ inÞPðG1 ¼ i1,G2 ¼ i2,.,Gn ¼ inÞ
#
PðDÞ
1

(1)
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Table A1. Residual Lifetime Risk of Developing Breast Cancer before Age 80 Years by Baseline Age at Test among FGFR2 Variant Carriers,
Noncarriers, and in the General Population
Using U.S. Breast Cancer
Incidence Rates of Non-Hispanic
White in 2003–2005
Assuming 1/3 of U.S. Breast
Cancer Incidence Rates of Non-Hispanic
White in 2003–2005
U.S. Non-Hispanic
White Women
in 2003–2005
Baseline
Age (yrs)
FGFR2 Variant Carriers,
% (95% SI)a
Noncarriers,
% (95% SI)a
FGFR2 Variant Carriers,
% (95% SI)a
Noncarriers,
% (95% SI)a % (95% CI)b
Birth 15.7 (15.5–15.8) 11.6 (11.5–11.8) 5.3 (5.2–5.3) 3.9 (3.8–4.0) 13.4 (13.3–13.5)
20 15.7 (15.6–15.8) 11.7 (11.5–11.8) 5.3 (5.2–5.3) 3.9 (3.8–4.0) 13.6 (13.5–13.6)
30 15.7 (15.5–15.8) 11.6 (11.5–11.8) 5.3 (5.2–5.3) 3.9 (3.8–4.0) 13.6 (13.5–13.5)
40 15.3 (15.2–15.4) 11.3 (11.2–11.5) 5.1 (5.0–5.2) 3.8 (3.7–3.8) 13.2 (13.1–13.3)
50 13.3 (13.1–13.4) 9.8 (9.7–10.0) 4.4 (4.3–4.5) 3.3 (3.2–3.3) 11.7 (11.6–11.7)
60 9.9 (9.8–10.0) 7.3 (7.2–7.5) 3.3 (3.2–3.3) 2.4 (2.3–2.5) 9.0 (8.9–9.0)
70 5.2 (5.1–5.3) 3.9 (3.8–4.0) 1.7 (1.7–1.8) 1.3 (1.2–1.3) 5.0 (5.0–5.1)
Abbreviations: SI, simulation interval; CI, confidence interval.
a Simulation interval was based on 10,000 Monte Carlo simulations. We assumed that the breast cancer incidence cases and number of deaths followed the Pois-
son distribution (when the number of incidence cases or number of deaths were large [n > 1000], normal distribution was used to approximate Poisson distri-
bution), genotype frequency and dominant risk ratio followed normal distribution with mean as point estimate and standard deviation as the difference between
upper and lower 95% confidence interval (CI) or 95% prediction interval (PI) divided by 3.92.
b Residual lifetime risk of developing breast cancer among U.S. non-Hispanic white women in 2003–2005 U.S. derived from DevCan software (version 6.3.1).cancer-free individuals at the start of the interval. The life-
time risk of developing breast cancer (from birth) is esti-
mated by dividing the sum of all expected breast cancer
cases in the life table by the number of individuals in the
initial birth cohort. The residual lifetime risk (age condi-
tional probability) of developing breast cancer (from any
speciﬁc age until certain age, e.g., age 80 years) is estimated
by dividing the sum of all expected breast cancer cases
from the age at test onward in the life table by the number
of individuals at age interval of the test.28,29 Detailed
descriptions of the lifetime table methodology to estimate
lifetime and residual lifetime risk have been published
elsewhere.28–30 In the estimates of lifetime risk among
the carriers of the genetic variants, we have replaced the
population-based age-speciﬁc incidence rates with our esti-
mated age-speciﬁc incidence rates as described in theMate-
rial and Methods section. We also calculated the residual
lifetime risk of developing breast cancer before age 80
when testing is not performed at birth but at different
ages X, e.g., at X ¼ 20, 30, 40, etc., years of age via the
life table method.31 Residual lifetime risk was estimated
separately for U.S. non-Hispanic women breast cancer inci-
dence rates from 2003–2005 and for the 3-fold downward
adjusted breast cancer incidence rates.
Table A1 lists the residual lifetime risk of developing
breast cancer before age 80 by baseline age at test among
carriers of FGFR2 genetic variant, noncarriers, and in
general population stratiﬁed by the U.S. non-Hispanic
women breast cancer incidence rates from 2003–2005 and
the 3-folddownward adjusted breast cancer incidence rates.
Table A2 lists the estimated residual lifetime risk of devel-
opingbreast cancerbybaseline age at test assumingadditive
or multiplicative joint effects of ﬁve genetic variants strati-
ﬁed by the different breast cancer incidence rates.The AmericanAcknowledgments
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Table A2. Residual Lifetime Risk of Developing Breast Cancer before Age 80 Years by Baseline Age at Test among Carriers of Five Genetic
Variants
Using U.S. Breast Cancer Incidence Rates
of Non-Hispanic White Women in 2003–2005
Assuming 1/3 of U.S. Breast Cancer Incidence
Rates of Non-Hispanic White Women in 2003–2005
Baseline
Age (yrs)
Additive Joint
Effect % (95% SI)a
Multiplicative Joint
Effect % (95% SI)a
Additive Joint
Effect % (95% SI)a
Multiplicative Joint
Effect % (95% SI)a
Birth 18.1 (17.0–19.3) 21.0 (18.8–23.3) 6.1 (5.7–6.5) 7.1 (6.3–7.9)
20 18.1 (17.0–19.3) 21.0 (18.8–23.3) 6.1 (5.7–6.5) 7.1 (6.3–7.9)
30 18.1 (17.0–19.2) 11.0 (18.8–23.3) 6.1 (5.7–6.5) 7.1 (6.3–7.9)
40 17.7 (16.7–18.9) 20.1 (18.3–22.9) 5.9 (5.5–6.3) 6.9 (6.1–7.7)
50 15.4 (14.3–16.5) 17.9 (15.6–20.2) 5.1 (4.7–5.5) 5.9 (5.2–6.7)
60 11.5 (10.5–12.6) 13.4 (11.4–15.6) 3.8 (3.5–4.2) 4.4 (3.8–5.1)
70 6.0 (5.3–6.9) 7.0 (5.6–8.7) 2.0 (1.8–2.3) 2.3 (1.8–2.9)
Abbreviations: SI, simulation interval.
a Simulation interval was based on 10,000 Monte Carlo simulations. We assumed that the breast cancer incidence cases and number of deaths followed the Pois-
son distribution (when the number of incidence cases or number of deaths were large [n > 1000], normal distribution was used to approximate Poisson distri-
bution), genotype frequency and dominant risk ratio followed the normal distribution with mean as point estimate and standard deviation as the difference
between upper and lower 95% confidence interval (CI) or 95% prediction interval (PI) divided by 3.92. The risk ratios of joint effect of five SNPs on additive
or multiplicative scale were calculated as defined in Material and Methods section. We took the lower 95% PI of risk ratio for each SNP, calculated the risk ratios
of joint effect on additive and multiplicative scale, respectively, and defined them as the minimum risk ratio in the Monte Carlo simulation. In a similar fashion, we
took the upper 95% PI of risk ratio for each SNP, calculated the risk ratios on additive and multiplicative scale, and defined them as the maximum risk ratio in the
simulation (defined as the triangle distribution with the mean value as the point estimate of risk ratio on additive or multiplicative scale).References
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